ライフサイエンスコーパス: NNT

1 NNT knockdown in a human adrenocortical cell line result

2 NNT makes a major contribution to peroxide metabolism du

3 NNT values were generally smaller for the period from 20

4 NNT-1/BSF-3 cDNA was cloned from activated Jurkat human

5 NNT-1/BSF-3 induces tyrosine phosphorylation of glycopro

6 NNT-1/BSF-3 is a gp130 activator with B-cell stimulating

7 NNT-1/BSF-3 mRNA is found mainly in lymph nodes and sple

8 NNT-1/BSF-3 regulates immunity by stimulating B cell fun

9 NNT-1/BSF-3 shows activities typical of IL-6 family memb

10 NNT-1/BSF-3 stimulates B cell proliferation and Ig produ

11 NNT-1/BSF-3-transgenic mice also show non-amyloid mesang

12 NNT-1/BSF-3-transgenic mice produce high amounts of Ag-s

13 NNT-1/BSF-3-transgenic mice show high serum levels of Ig

14 NNT-1/BSF-3-transgenic mice, engineered to express NNT-1

15 NNTs were lower for tricyclic antidepressants, strong op

16 NNTs were lowest for MSM and transgender women self-repo

17 0 [95% CI -169/10,000 to -26/10,000], I2 0%, NNT 103 [95% CI 59 to 385]).

18 00, [95% CI -56/10,000 to -5/10,000], I2 0%, NNT 326, [95% CI 177 to 2,014]) and admission to a neona

19 , [95% CI -204/10,000 to -50/10,000], I2 0%, NNT 79 [95% CI 49 to 201]) but not for multiparous women

20 ity (RR, 0.64; 95% CI, 0.46 to 0.89; I2, 0%; NNT, 23) in patients receiving ventilation with lower ti

21 I, 0.48-0.97]; ARD, -4% [95% CI, -7% to 0%]; NNT, 26 [95% CI, 13-372]) were associated with moderate

22 93), quetiapine (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and risperidone (OR, 1.83, 95% CI, 1.16-2.88;

23 ontrol restorations, 38 (42%) (p < 0.000001; NNT 3).

24 ontrol restorations, 60 (46%) (p < 0.000001; NNT 3).

25 ontrol restorations, 22 (17%) (p = 0.000004; NNT 7); and 'Minor' failures, HT, 7 (5%); control restor

26 trol restorations, 15 (16.5%) (p = 0.000488; NNT 8); and 'Minor' failures (reversible pulpitis, resto

27 eralized anxiety (N=22,394, g=0.26, p<0.001, NNT=12.4) as compared to control groups.

28 lications (-0.13, -0.22 to -0.06, P < 0.001; NNT 8).

29 th (RR 0.74, 95% CI [0.66, 0.84]; p < 0.001; NNT, 7, 95% CI [6,11]).

30 ors (RR, 0.63 [95% CI, 0.50-0.80]; P < .001; NNT, 105 [95% CI, 69-212]), 3 factors (RR, 0.54 [95% CI,

31 ears (RR, 0.84; 95% CI, 0.79-0.89; P < .001; NNT, 17).

32 ore (RR, 0.40 [95% CI, 0.25-0.73]; P < .001; NNT, 18 [95% CI, 12-34]).

33 year (RR, 0.77; 95% CI, 0.71-0.84; P < .001; NNT, 21) and 2 years (RR, 0.94; 95% CI, 0.89-1.00; P = .

34 year (RR, 0.66; 95% CI, 0.43-0.99; P < .001; NNT, 26).

35 est (RR, 0.67 [95% CI, 0.57-0.79]; P < .001; NNT, 339 [95% CI, 240-582]), again limited to patients u

36 ors (RR, 0.54 [95% CI, 0.39-0.73]; P < .001; NNT, 41 [95% CI, 28-80]), or 4 factors or more (RR, 0.40

37 the RR was 0.19 (95% CI, 0.06-0.53; P=.002; NNT, 15).

38 cardiac mortality (0.67, 0.51-0.89; p=0.006; NNT=347), with similar cardiac mortality (0.93, 0.73-1.1

39 ean (OR = 0.53; 95% CI: 0.33-0.87; P = 0.01; NNT = 30) and clean-contaminated surgery (OR = 0.43; 95%

40 NT, 5) and chronicity (chi2 = 7.46; P = .02; NNT, 6) such that the advantage for combined treatment w

41 ividuals (IRD% -0.06 (95% CI: -0.09, -0.03); NNT: 1667) and no difference among South Asian individua

42 ery (OR = 0.43; 95% CI: 0.20-0.93; P = 0.03; NNT = 9) specifically.

43 osure ranged from 1.13 to 10.12 (P = 0.030) (NNT 12), with a mean visual acuity improvement of -0.18

44 years (RR, 0.94; 95% CI, 0.89-1.00; P = .04; NNT, 593).

45 actions with severity (t451 = 1.97; P = .05; NNT, 5) and chronicity (chi2 = 7.46; P = .02; NNT, 6) su

46 83.7%; RR, 1.21; 95% CI, 1.00-1.46; P = .05; NNT, 6.9).

47 pregnated catheters (-1.98%, -3.90 to -0.06, NNT 51, 26-1667).

48 vents were nonfatal 1.7% (95% CI 0.5%-2.1%), NNT = 59 (95% CI 48-194); total 1.6% (95% CI 0.2%-2.2%),

49 , 0.57-0.83]; ARD, -3% [95% CI, -4% to -1%]; NNT, 34 [95% CI, 22-67]) and prophylactic ethamsylate (R

50 ssion at week 8 (RR, 4.5 [95% CI, 1.4-14.1]; NNT = 2.45; P = .01).

51 ized for a hospital threshold volume of 100 (NNT=50) and a surgeon threshold volume of 50 (NNT=118).

52 This was true both overall (for CAC>=100, NNT(5)=140 versus NNH(5)=518) and within ASCVD risk stra

53 22-0.74; 1.17% [12/1024] vs 3.04% [31/1019]; NNT = 54).

54 54.8%; RR, 1.26; 95% CI, 0.95-1.68; P = .11; NNT, 6.9).

55 onths (RR, 0.72; 95% CI, 0.48-1.09; P = .12; NNT, 14) and 1 year (RR, 0.66; 95% CI, 0.43-0.99; P < .0

56 ividuals (IRD% -0.49 (95% CI: -0.79, -0.18); NNT: 204) compared with White individuals (IRD% -0.06 (9

57 % CI 48-194); total 1.6% (95% CI 0.2%-2.2%), NNT = 61 (95% CI 46-472); and for fractures 3.6% (95% CI

58 acebo/UC in terms of response rate (RR=0.22, NNT=2), delirium severity scales scores (SMD=-1.27), CGI

59 neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3).

60 neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3; also reported as cardiotrophin-like cytokin

61 on (RR, 0.45; 95% CI, 0.22 to 0.92; I2, 32%; NNT, 26), lower mean (SD) hospital length of stay (6.91

62 cination course (RR, 0.28 [95% CI, .25-.32]; NNT, 17) regardless of age and the delay since the last

63 37.9%; RR, 1.21; 95% CI, 0.82-1.81; P = .35; NNT, 12.4) or at week 20 (69.3% vs 54.8%; RR, 1.26; 95%

64 RR=0.80, CI: 0.70-0.91, P=0.0007, I(2)=37%; NNT=17, CI: 10-50, P=0.003).

65 ; and for fractures 3.6% (95% CI 0.8%-5.4%), NNT = 28 (95% CI 19-125).

66 ause (OR 0.69, 0.62-0.78; ARR 2.7%, 2.0-3.5; NNT 37, 29-52), implying that 145 self-harm episodes and

67 vs 3/26 [11.5%]; RR, 4.0 [95% CI, 1.2-12.5]; NNT = 2.86; P = .01; and 25% response, 18/28 [64.2%] vs

68 NT=50) and a surgeon threshold volume of 50 (NNT=118).

69 3.96; P = .001; HR, 2.34; 95% CI, 1.54-3.57; NNT, 3; 95% CI, 2-5).

70 At P-6, NNT treatment decreased 5-HT levels slightly compared wi

71 elopment of HE (RR = 0.47, 95% CI 0.33-0.68, NNT = 6), the risk of developing serious liver-related a

72 renal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT = 50).

73 39-0.80; treatment-control difference, 1.7%; NNT, 60).

74 adverse events (RR = 0.48, 95% CI 0.33-0.70, NNT = 6), and reduced mortality (RR = 0.63, 95% CI 0.40-

75 bation failure (RR, 0.48; 95% CI, 0.32-0.71; NNT, 4; 95% CI, 2-7) compared with placebo or no treatme

76 : aripiprazole (OR, 2.07; 95% CI, 1.58-2.72; NNT, 7), OFC (OR, 1.30, 95% CI, 0.87-1.93), quetiapine (

77 s; relative risk 0.36 [95% CI 0.17 to 0.73]; NNT 7.6).

78 40) or delayed antibiotics (0.61, 0.50-0.74; NNT 18).

79 nts (relative risk, 0.58; 95% CI, 0.44-0.77; NNT, 6; 95% CI, 4-13).

80 bation failure (RR, 0.70; 95% CI, 0.60-0.81; NNT, 8; 95% CI, 5-13).

81 physiotherapy (RR, 0.32; 95% CI, 0.13-0.82; NNT, 15; 95% CI, 7-50) both reduced extubation failure r

82 82.5%; RR, 1.01; 95% CI, 0.88-1.17; P = .84; NNT, 84).

83 nd risperidone (OR, 1.83, 95% CI, 1.16-2.88; NNT, 8).

84 cide (OR 0.75, 0.60-0.94; ARR 0.5%, 0.1-0.9; NNT 188, 108-725), and death by any cause (OR 0.69, 0.62

85 vs 8/26 [30.8%]; RR, 2.1 [95% CI, 1.1-3.9]; NNT = 2.99; P = .01).

86 with overt HE (RR = 0.36, 95% CI 0.14-0.94, NNT = 20), although not in patients with minimal HE.

87 also reduced by immediate (0.83, 0.73-0.94; NNT 40) or delayed antibiotics (0.61, 0.50-0.74; NNT 18)

88 orticosteroids (RR, 0.18; 95% CI, 0.04-0.97; NNT, 12; 95% CI, 6-100) and chest physiotherapy (RR, 0.3

89 uced mortality (RR = 0.63, 95% CI 0.40-0.98, NNT = 20).

90 rescription of antibiotics (0.58, 0.34-0.98; NNT 174).

91 the middle predicted benefit subgroup had a NNT of 76 (ARR = 0.013, 95% CI: -0.0001, 0.026; P = 0.05

92 of 0.91 (95% CI, 0.84-0.98), resulting in a NNT of 12 (95% CI, 7-78).

93 tainty of evidence), botulinum toxin (BTX-A) NNT=2.7 (1.8-9.61), NNH=216.3 (23.5-infinity; moderate c

94 nt(-/-) exhibit approximately 50% and absent NNT activity, respectively, but the activities of concur

95 25.1 million women were perfectly adherent; NNT would be 96.

96 s with eGFR<30 ml/min per 1.73 m(2) Adjusted NNT (95% confidence interval) to avoid dialysis was 22.4

97 risk patients with LDL-C >/=70 mg/dl, and an NNT </=30 for very high-risk and high-risk patients with

98 isk patients with LDL-C >/=190 mg/dl, and an NNT </=30 for very high-risk patients with LDL-C >/=160

99 lower LDL-C by at least 50% would provide an NNT </=50 for very high-risk and high-risk patients with

100 pursued in 2 of these patients, yielding an NNT to avoid 1 advanced imaging study of 115 (95% CI, 32

101 .5 to <1.0 mg/L) D-dimer values, yielding an NNT to avoid 1 advanced imaging study of 2.3 (95% CI, 2.

102 d from 837 at year 10 to 503 at year 12, and NNT decreased from 29 to 18.

103 ARR and NNT for cardiovascular events were nonfatal 1.7% (95% CI

104 eptibility between NNT-deficient 6J mice and NNT-competent C57BL/6 substrains.

105 NNT 44 for PCI-related delay 60-90 min; and NNT 250 for PCI-related delay >90 min].

106 val study setting such as the ERSPC, NNS and NNT are time specific, and reporting values at one time

107 Although NNS and NNT are useful statistics to assess the benefits and har

108 According to our model, the NNS and NNT at 9 years were 1,254 and 43, respectively.

109 effect of varying follow-up times on NNS and NNT using data extrapolated from the ERSPC report.

110 Consideration of the PAF and NNT can aid in discussion of the benefits and risks of p

111 Poisson model, and we calculated the PAF and NNT for risk behaviour subgroups.

112 We aimed to estimate the PAF and NNT of participants in the iPrEx (Pre-Exposure Prophylax

113 Of 359 eligible articles, NNT was reported in 8 articles.

114 red metabolic disease susceptibility between NNT-deficient 6J mice and NNT-competent C57BL/6 substrai

115 imary measure and assessed publication bias; NNT was calculated with the fixed-effects Mantel-Haensze

116 to changes in oxygen consumption mediated by NNT.

117 re generally modest: in particular, combined NNTs were 6.4 (95% CI 5.2-8.4) for serotonin-noradrenali

118 receptive anal intercourse without a condom (NNT 36), cocaine use (12), or a sexually transmitted inf

119 low certainty of evidence), capsaicin cream NNT=6.1 (3.1-infinity), NNH=18.6 (10.6-77.1; very low ce

120 Importantly, knocking down NNT inhibits reductive carboxylation in SkMel5 and 786-O

121 epidemiological impact (PIA) and efficiency (NNT) at plausible scale-up levels.

122 A number needed to treat/enroll (NNT) for 1 additional person to achieve viral suppressio

123 A number needed to treat/enroll (NNT) for one additional person to achieve viral suppress

124 The estimated NNT for routine PPI use to prevent one disabling or fata

125 r were upper gastrointestinal, the estimated NNT for routine PPI use to prevent such bleeds is low, a

126 he seemingly simplistic nature of estimating NNT, there is widespread misunderstanding of its pitfall

127 ; number needed to treat to prevent 1 event [NNT], 48).

128 BSF-3-transgenic mice, engineered to express NNT-1/BSF-3 in the liver under control of the apolipopro

129 The gene for NNT-1/BSF-3 is on chromosome 11q13.

130 Our results demonstrate a novel role for NNT as a regulator of macrophage-mediated inflammatory r

131 ratio (RR), the number-needed-to-treat/harm (NNT/NNH), 95% CIs and standardised mean difference (SMD)

132 ve anal sex without a condom had the highest NNTs (100 and 77, respectively).

133 lementation studies showed that mutant human NNT failed to rescue nnt morpholino-induced heart dysfun

134 dentified, which shows 96% homology to human NNT-1/BSF-3.

135 In NNT-treated rats, the Di-I-labeled vibrissae-related pat

136 7BL/6J phenotype but the parameters of CP in NNT-expressing transgenic mice generated on a C57BL6/J b

137 l proteins including consistent increases in NNT, a mitochondrial protein with essential roles in inf

138 mily, we identified a frameshift mutation in NNT, a nuclear-encoded mitochondrial protein, not implic

139 exome sequencing, we identified mutations in NNT, an antioxidant defense gene, in individuals with fa

140 loss-of-function to determine whether intact NNT is necessary for the pathological cardiac manifestat

141 OR 0.36, 0.26-0.50) in myocardial ischaemia (NNT 16) at the expense of an increase (OR 2.01, 1.27-3.6

142 times daily (5x/day), with either 0.1 mg/kg NNT or vehicle from birth to postnatal day 6 (P-6).

143 certainty of evidence), alpha2delta-ligands NNT=8.9 (7.4-11.10), NNH=26.2 (20.4-36.5; moderate certa

144 ciated with greater risk of sepsis and lower NNT.

145 be defective in C57BL/6J mice, and no mature NNT protein could be detected.

146 es included regulators of energy metabolism (NNT), trafficking and membrane fusion (SLCO2A1 and ANXA7

147 reat (NNT) 23 for PCI-related delay >60 min; NNT 44 for PCI-related delay 60-90 min; and NNT 250 for

148 iority of SGAs regarding relapse was modest (NNT=17), but confirmed in double-blind trials, first- an

149 ther administration of 5-nonyloxytriptamine (NNT), a selective 5-HT(1B) receptor agonist, affects TCA

150 results indicate that the agonist action of NNT at the 5-HT(1B) receptor causes TCA disorganization

151 This action of NNT could explain its putative protective role in MnSOD-

152 kedly influence the relative contribution of NNT (i.e. varies between nearly 0 and 100%) to NADPH-dep

153 The contribution of NNT to peroxide metabolism is decreased during ADP phosp

154 Here, we show that knockdown of NNT inhibits the contribution of glutamine to the TCA cy

155 The lack of NNT activity in Nnt(-/-) mice impairs peroxide metabolis

156 variances in the 6J stain, including loss of NNT function, these findings suggest that the 6N substra

157 Additionally, genetic modification of NNT in zebrafish alters melanocytic pigmentation.

158 Overexpression of NNT in a macrophage cell-line resulted in decreased leve

159 Overexpression of NNT is sufficient to stimulate glutamine oxidation and r

160 The forward reaction of NNT, a nuclear-encoded mitochondrial inner membrane prot

161 Resequencing of NNT in additional LVNC families identified a second like

162 Our findings underscore the role of NNT in regulating central carbon metabolism via redox ba

163 authors expressed their findings in terms of NNT or ARR.

164 (16,739-65,709) in girls; over 85 years old, NNT was 262 (236-293) in men and 385 (352-421) in women.

165 ty; moderate certainty of evidence), opioids NNT=5.9 (4.1-10.7), NNH=15.4 (10.8-24.0; low certainty o

166 The overall NNT per year for the cohort was 62 (95% CI 44-147).

167 The overall NNT(5) with aspirin to prevent 1 cardiovascular disease

168 5) was much higher than the NNH(5) (overall, NNT(5)=1190 versus NNH(5)=567).

169 certainty of evidence), capsaicin 8% patches NNT=13.2 (7.6-50.8), NNH=1129.3 (135.7-infinity; moderat

170 t doses must be administered to 12 patients (NNT, 12.2; 95% CI, 7.5 to 33.4) not receiving dexamethas

171 = 0.16; responder rate, 60% DES vs. 47% PLA; NNT, 8.1) but did show a statistically significant benef

172 = 0.01; responder rate, 73% DES vs. 49% PLA; NNT, 5.2), especially when participants with nondetectab

173 ertainty of evidence), lidocaine 5% plasters NNT=14.5 (7.8-108.2), NNH=178.0 (23.9-infinity; very low

174 Pooled NNT to prevent one symptomatic VTE or VTE-related death

175 The predicted NNT for the guidelines would be 25.

176 llion women were perfectly adherent to PrEP; NNT would be 61.

177 d a very low event rate and a high projected NNT.

178 QHPs' NNT for an additional person to achieve VS is 20 (14.1-3

179 reporting methods (relative risk reduction, NNT, and ARR).

180 ed through pyruvate carboxylase and rendered NNT knockdown cells more sensitive to glucose deprivatio

181 0.39), and 0.55 (0.43-0.71), with respective NNTs of 4.1, 6.7, and 5.3.

182 ht gain >=7% (27.5% and 42.7%, respectively; NNT=6.29; odds ratio=0.50).

183 ive transcranial magnetic stimulation (rTMS) NNT=4.2 (2.3-28.3), NNH=651.6 (34.7-infinity; low certai

184 d norepinephrine reuptake inhibitors (SNRIs) NNT=7.4 (5.6-10.9), NNH=13.9 (10.9-19.0; moderate certai

185 tcomes were tricyclic antidepressants (TCAs) NNT=4.6 (95% CI 3.2-7.7), NNH=17.1 (11.4-33.6; moderate

186 methods are the nearest neighbor technique (NNT) and Moran's IPOP technique, a variation of Moran's

187 sulin resistance, coupled with the fact that NNT regulates peroxide detoxification, it was hypothesiz

188 We found that NNT expression significantly enhances tumor formation an

189 We found that NNT mRNA is enriched in immune system-related tissues an

190 We further show that NNT loss elicits mitochondrial dysfunction independent o

191 A new study by Smith et al. shows that NNT activity maintains low ROS levels by means of a fine

192 Our results suggest that NNT may have a role in ROS detoxification in human adren

193 bility and ROS accumulation, suggesting that NNT serves a specific role in mitigating the oxidation o

194 udy, we demonstrated for the first time that NNT has a significant effect in the modulation of the im

195 The NNT to prevent return to any drinking for acamprosate wa

196 The NNT to prevent return to heavy drinking was 12 (95% CI,

197 The NNT was 14 (95% CI 8-50), suggesting that approximately

198 The NNT(5) was also greater than or similar to the NNH(5) am

199 ed due to elevated PM2.5 (AQI, 101-200), the NNT to prevent a serious disease event remained very hig

200 performance of the entropy technique and the NNT were independent of scale, that of Moran's IPOP was

201 For partial (>/=75%) clearance the NNT was 1.8 (1.7-2.0).

202 health investment in PrEP by decreasing the NNT.

203 For cardiovascular disease, the NNT was 124, 54, and 19.

204 mortality difference continues to grow, the NNT to save a life with PSA screening will decrease.

205 At 0-4 years old, the NNT was 29,773 (95% UI 18,458-71,091) in boys and 27,014

206 bapenemase testing criteria would reduce the NNT by half and can be implemented in most clinical labo

207 jointly raise the PIA, but reductions to the NNT were associated with better adherence only.

208 for the first three cutoff levels using the NNT.

209 784 (602-1,051) in women; following UTI, the NNT was 121 (102-145) in men and 284 (241-342) in women.

210 lso, CAC=0 identified subgroups in which the NNT(5) was much higher than the NNH(5) (overall, NNT(5)=

211 in men and 2,278 (1,966-2,686) in women; the NNT following skin infection was 503 (398-646) in men an

212 At 65-74 years, the NNT following RTI was 1,257 (1,112-1,434) in men and 2,2

213 everely frail patients aged 55-64 years, the NNT was 247 (156-459) in men and 343 (234-556) in women.

214 sfusion than those without thrombocytopenia (NNT = 5).

215 A murine equivalent to NNT-1/BSF-3 also was identified, which shows 96% homolog

216 rmed (LHH) was calculated as ratio of NNH to NNT.

217 ctive stress-induced JH(2)O(2) production to NNT-linked redox buffering circuits provides a potential

218 tes highly expressed genes are biased toward NNT instead of NNC.

219 Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial enzyme that transfers reducing e

220 Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial redox-driven proton pump that co

221 Nicotinamide nucleotide transhydrogenase (NNT) is known to sustain mitochondrial antioxidant capac

222 of nicotinamide nucleotide transhydrogenase (NNT) protein in C57BL/6J is responsible for the more sev

223 of nicotinamide nucleotide transhydrogenase (NNT) reduces NADP(+) at the expense of NADH oxidation an

224 gh nicotinamide nucleotide transhydrogenase (NNT)-deficient C57BL/6J (6J) mice are known to be highly

225 nt nicotinamide nucleotide transhydrogenase (NNT).

226 by nicotinamide nucleotide transhydrogenase (NNT).

227 nd nicotinamide nucleotide transhydrogenase (NNT)], we selectively impaired mitochondrial respiratory

228 A low number needed to treat (NNT = 5) suggests MP may be more efficacious than dexame

229 used for the 5-year number needed to treat (NNT(5)) calculations, and a 42% relative risk increase i

230 ty benefit of X-PCI [number needed to treat (NNT) 23 for PCI-related delay >60 min; NNT 44 for PCI-re

231 to -0.06, P = 0.006; number needed to treat (NNT) 7) and infectious complications (-0.13, -0.22 to -0

232 .33-0.77; P = 0.001; number needed to treat (NNT) = 21; I = 75%].

233 alculated the 5-year number needed to treat (NNT) after stratification based on the CAC score.

234 The number needed to treat (NNT) analysis indicated that 562 (95% CI 366-1,210) indu

235 cit reporting of the number needed to treat (NNT) and the absolute risk reduction (ARR) in RCTs.

236 The number needed to treat (NNT) at higher-volume providers to avoid a death was min

237 We calculated 5-year number needed to treat (NNT) by applying the benefit recorded in JUPITER to the

238 eductions (ARR) and numbers needed to treat (NNT) for 5-HT(3) antagonists, as monotherapy or as adjun

239 We used number needed to treat (NNT) for 50% pain relief as a primary measure and assess

240 lative risks and the number needed to treat (NNT) for first variceal bleed, bleed-related mortality,

241 ith vehicle, and the number needed to treat (NNT) for one patient to have their keratosis completely

242 , corresponding to a number needed to treat (NNT) of 10 (95% CI, 7 to 15), 6 (4 to 8), and 3 (2 to 5)

243 nefit subgroup had a number needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (ab

244 rates by 72%, with a number needed to treat (NNT) of 38.7, to prevent a cervical cancer death.

245 (NNS) of 1,410 and a number needed to treat (NNT) of 48 to prevent one prostate cancer death at 9 yea

246 The number needed to treat (NNT) to benefit was 21 (95% CI 14 to 41) women/fetus to

247 The number needed to treat (NNT) to benefit was 41 women/babies to prevent 1 baby fr

248 sed to determine the number needed to treat (NNT) to prevent 1 ASCVD event over 5 years for each pati

249 F]) and for whom the number needed to treat (NNT) to prevent infection is lowest.

250 We calculated the number needed to treat (NNT) to prevent one ASCVD event and the number needed to

251 The pooled number needed to treat (NNT) to prevent one symptomatic or fatal VTE event and t

252 imated age-specific numbers needed to treat (NNT) to prevent upper gastrointestinal bleeding with rou

253 verted (PIA) and the number needed to treat (NNT) under behavioral indications of the CDC's PrEP guid

254 risk difference, the number needed to treat (NNT) was 15 (95% CI, 8-53), or equivalently 15 patients

255 The number needed to treat (NNT) was 175 (95% CI 94 to 1,267).

256 The number needed to treat (NNT) was 19 for OFC and nine for each other drug.

257 The number needed to treat (NNT) was calculated by taking the inverse of the pooled

258 The number needed to treat (NNT) with FB-CBT vs FB-RT was estimated as 3.2 (95% CI,

259 The number needed to treat (NNT) with restrictive strategies to prevent serious infe

260 effects model, with numbers-needed-to-treat (NNT) calculations where appropriate.

261 ) corresponding to a number-needed-to-treat (NNT) of 14 patients.

262 % CI: -1.10, -0.63); number-needed-to-treat (NNT): 115), and no differences in South Asian individual

263 ow-risk groups with numbers needed to treat (NNTs) to prevent one disease recurrence being 11, 21, an

264 ductions (ARRs) and numbers needed to treat (NNTs) were estimated.

265 Adjusted numbers needed to treat (NNTs; 95% confidence interval) to avoid composite primar

266 0.43-0.91, estimated number needed to treat [NNT 193) as was delayed prescription of antibiotics (0.5

267 70% CBT vs. 37% EDU; number needed to treat [NNT ], 3.1).

268 ARR] 2.6%, 1.5-3.7; numbers needed to treat [NNT] 39, 95% CI 27-69), deaths by suicide (OR 0.75, 0.60

269 % CI -4.09 to -0.20; number needed to treat [NNT] 47, 95% CI 25-500) and antibiotic-impregnated cathe

270 CI 1.1-3.7], p=0.03; number needed to treat [NNT] 6.6 [95% CI 3.5-81.8]).

271 ocardial infarction (number needed to treat [NNT] 63) and decrease (OR 0.36, 0.26-0.50) in myocardial

272 5% CI 0.42 to 0.97]; number needed to treat [NNT] 8.0) and re-hospitalization (9 [7.3%] of 123 interv

273 I: -0.50% to 0.058%; number needed to treat [NNT] = 359).

274 rval [CI] 0.53-0.74, number needed to treat [NNT] = 4) and serious liver-related adverse events such

275 with anticoagulants; number needed to treat [NNT] = 59) and greater risks of major bleeding (OR, 2.73

276 e episode of sepsis (number needed to treat [NNT]) decreased with age.

277 ; 95% CI, 1.06-1.68; number needed to treat [NNT], 10; 95% CI, 5-72).

278 .23 to 0.47; I2, 0%; number needed to treat [NNT], 11), and mortality (RR, 0.64; 95% CI, 0.46 to 0.89

279 ; 95% CI, 0.81-0.98; number needed to treat [NNT], 11; 95% CI, 6-54).

280 ol difference, 6.5%; number needed to treat [NNT], 15), but there was no significant reduction among

281 1.2-12.5]; P = .01; number needed to treat [NNT], 2.86).

282 , 0.65-0.83; P < .001; number need to treat [NNT], 241; 95% CI, 173-397).

283 1.16-1.95; P = .002; number needed to treat [NNT], 3.6) suggested the efficacy of CGT, and the additi

284 ; 95% CI, 0.48-0.72; number needed to treat [NNT], 6; 95% CI, 3-9).

285 0.56-0.69; P < .001; number needed to treat [NNT], 9) and 2 years (RR, 0.84; 95% CI, 0.79-0.89; P < .

286 I 0.69-0.98; p=0.02; number needed to treat [NNT]=325), with no significant heterogeneity apparent ac

287 29.8%, respectively; number needed to treat [NNT]=7.29; odds ratio=0.50) and weight gain >=7% (27.5%

288 67, g=0.28, p<0.001; number needed to treat, NNT=11.5) and generalized anxiety (N=22,394, g=0.26, p<0

289 A total of 5 patients needed to be treated (NNT-value) to prevent 1 IAP.

290 95% CI 0.53 to 0.87, 3,988 babies, 4 trials, NNT to benefit 42).

291 95% CI 0.54 to 0.87, 4,601 babies, 5 trials, NNT to benefit 46) and the neuroprotective intent analys

292 rn, the rate at which energy is expended via NNT-mediated proton conductance.

293 0 and CAC>=400 identified subgroups in which NNT(5) was lower than NNH(5).

294 st variceal bleed was 0.48 (0.24-0.96), with NNT of 13; however, there was no effect on either bleed-

295 dL, the RR was 0.82 (95% CI, 0.70-0.97) with NNT of 20 (95% CI, 12-133).

296 Normal mice treated with NNT-1/BSF-3 also produce high amounts of Ag-specific IgE

297 rious single-nucleotide polymorphisms within NNT.

298 -density LDL-C by 20% would provide a 5-year NNT </=50 for very high-risk patients with LDL-C >/=130

299 The estimated 5-year NNT to prevent 1 CVD event ranged from 81-130 for patien

300 coronary heart disease, the predicted 5-year NNT was 549 for CAC score 0, 94 for scores 1-100, and 24

301 te difference was 219 per 1000 person years (NNT of 5).